CKD (6407) Fundamentals 2026 — P/E 32.3x, Revenue Analysis | SniperIQ
CKD (6407) is a JP-listed Industrials company in Industrial - Machinery with a market capitalization of ¥439.1B, trading at ¥6570.00 on the JPX. This SniperIQ fundamentals page covers CKD's valuation (P/E 32.3x, P/B 2.9x), profitability (net margin 8.6%), revenue (¥157.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CKD's market cap?
CKD (6407) has a market capitalization of approximately ¥439.1B, trading at ¥6570.00 on the JPX. Market cap moves with the live share price.
What is CKD's P/E ratio?
CKD's trailing twelve-month P/E ratio is 32.3x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is CKD?
CKD runs a net profit margin of 8.6%, a gross margin of 29.7%, and an operating margin of 12.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CKD generate?
CKD reported revenue of ¥157.9B for fiscal year 2025, with net income of ¥13.6B and earnings per share (EPS) of 203.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CKD pay a dividend?
CKD offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is CKD financially healthy?
CKD carries a debt-to-equity ratio of 0.23x and a current ratio of 3.43x, with a market beta of 1.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CKD a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CKD (6407) the key facts are: market cap ¥439.1B, P/E 32.3x, revenue ¥157.9B, 52-week range 2361-8330. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track CKD's full fundamentals live
Get CKD's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.